Cerebrospinal fluid penetration of tigecycline

Pallotto, Carlo; Fiorio, Maurizio; D’Avolio, Antonio; Sgrelli, Alessio; Baldelli, Franco; Perri, Giovanni Di; Socio, Giuseppe Vittorio De

doi:10.3109/00365548.2013.837957

Cited by 22 publications

(25 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravenous tigecycline for treatment of our patient resulted in poor efficacy despite it being performed in accordance with the instructions, but intrathecal injection enabled tigecycline to fully exert its therapeutic effect, restoring CSF to a completely normal state within 6 days. The treatment outcome suggests that intravenous tigecycline could not reach the minimum inhibitory concentration in the CSF as previously reported 5 6…”

Section: Discussionsupporting

confidence: 70%

See 1 more Smart Citation

Intrathecal injection of tigecycline in treatment of multidrug-resistantAcinetobacter baumanniimeningitis: a case report

Wang

Zhang

et al. 2016

Eur J Hosp Pharm

View full text Add to dashboard Cite

The ubiquitous Acinetobacter baumannii is an important and troublesome pathogen of nosocomial infection. Multidrug-resistant A baumannii meningitis is very difficult to treat, usually with high mortality. The disease is generally associated with craniotomy, but rarely with lumbar puncture. However, in our case, a 45-year-old male construction worker suffered multidrug-resistant A baumannii meningitis associated with lumbar puncture. The patient responded poorly to the initial treatment with an intravenous infusion of tigecycline. However, later treatment with an intrathecal injection of tigecycline (concentration 1 mg/mL) at a dose of 10 mg every 12 hours proved to be highly efficacious. Thus, intrathecal injection of tigecycline should be seriously considered as a treatment for multidrug-resistant A baumannii meningitis.

show abstract

Section: Discussionsupporting

confidence: 70%

“…Treatment of the disease can be very difficult. It has been shown that intravenous infusion of tigecycline results in low cerebrospinal fluid (CSF) concentrations,5 6 and it fails to achieve a clinical response in the treatment of A baumannii cerebritis 5…”

Section: Introductionmentioning

confidence: 99%

Intrathecal injection of tigecycline in treatment of multidrug-resistantAcinetobacter baumanniimeningitis: a case report

Wang

Zhang

et al. 2016

Eur J Hosp Pharm

View full text Add to dashboard Cite

show abstract

“…HPLC has been extensively used for the estimation of TIG in biological samples (Rodvold et al, 2006, Ji et al, 2007, Pallotto et al, 2014, Xie et al, 2014. However, relatively few parameters, such as mobile phase composition, analysis time, reproducibility, detection limit and obtaining a suitable IS, have been reported, making it difficult for these few methods to be used for widespread applications (Xie et al, 2014).…”

Section: Application Of Method: Brain Distribution Studiesmentioning

confidence: 99%

“…TIG concentrations were lower when compared with those of other drugs in the tetracycline family and it was concluded that inflamed meninges may facilitate the drug's penetration of the CSF (Nau et al ., ). In a couple of cases, the CSF concentrations were determined to be lower than the minimum inhibitory concentration (MIC) (Lengerke et al ., , Pallotto et al ., ), but in most of the reported cases they were constantly above the MIC (Pankey and Ashcraft, , Ray et al ., , Dandache et al ., ). These results warrant further investigations into the neuroprotective properties of TIG.…”

Section: Introductionmentioning

confidence: 99%

“…Amongst these disorders is acute bacterial meningitis, which is a life-threatening infectious disease. Despite its high efficacy against multidrug-resistant (MDR) pathogens, TIG is currently being reviewed for the treatment of meningeal infections based on studies of it in cerebrospinal fluid (CSF) (Rodvold et al, 2006, Lengerke et al, 2011, Pallotto et al, 2014. TIG concentrations were lower when compared with those of other drugs in the tetracycline family and it was concluded that inflamed meninges may facilitate the drug's penetration of the CSF (Nau et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development and validation of a liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) method for the quantification of tigecycline in rat brain tissues

Munyeza

Shobo

Baijnath

et al. 2015

Biomedical Chromatography

View full text Add to dashboard Cite

Tigecycline (TIG), a derivative of minocycline, is the first in the novel class of glycylcyclines and is currently indicated for the treatment of complicated skin structure and intra-abdominal infections. A selective, accurate and reversed-phase high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed for the determination of TIG in rat brain tissues. Sample preparation was based on protein precipitation and solid phase extraction using Supel-Select HLB (30 mg/1 mL) cartridges. The samples were separated on a YMC Triart C18 column (150 mm x 3.0 mm. 3.0 µm) using gradient elution. Positive electrospray ionization (ESI+) was used for the detection mechanism with the multiple reaction monitoring (MRM) mode. The method was validated over the concentration range of 150-1200 ng/mL for rat brain tissue. The precision and accuracy for all brain analyses were within the acceptable limit. The mean extraction recovery in rat brain was 83.6%. This validated method was successfully applied to a pharmacokinetic study in female Sprague Dawley rats, which were given a dose of 25 mg/kg TIG intraperitoneally at various time-points. Copyright © 2015 John Wiley & Sons, Ltd.

show abstract

Development and validation of an LC‐MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study

Mei

Luo

et al. 2016

Biomedical Chromatography

View full text Add to dashboard Cite

Tigecycline (TGC) is an important antibiotic in treating various drug-resistant bacteria. The dosage regimen for cerebral intraventricular TGC is still unknown. The aim of the study was to develop and validate liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods for the determination of TGC in human plasma and cerebrospinal fluid (CSF) to obtain an applicable regimen. The ion transitions under ESI positive model were performed at m/z 586.3 > 513.2 and m/z 595.3 > 514.3 for TGC and d9-TGC internal standard (IS). For plasma and CSF samples, the calibration curve of TGC was linear within the ranges 25-2000 and 250-100,000 ng/mL; the IS normalized matrix effect was within the ranges 96.46-101.06% and 101.13-103.58%, respectively, for all. TGC was stable under all tested conditions. The patient received 1 mg intraventricular and 49 mg intravenous administration of TGC. The AUC in plasma and CSF calculated according to our noncompartment model were 4713 and 23,0238 h ng/mL, respectively. Given our findings cerebral intraventricular TGC may be a choice for clinicians to treat drug-resistant Gram-negative bacterial-induced meningitis and the safety and efficacy of this administration route warrants further study.

show abstract

Cerebrospinal fluid penetration of tigecycline

Cited by 22 publications

References 6 publications

Intrathecal injection of tigecycline in treatment of multidrug-resistantAcinetobacter baumanniimeningitis: a case report

Intrathecal injection of tigecycline in treatment of multidrug-resistantAcinetobacter baumanniimeningitis: a case report

Development and validation of a liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) method for the quantification of tigecycline in rat brain tissues

Development and validation of an LC‐MS/MS method for the determination of tigecycline in human plasma and cerebrospinal fluid and its application to a pharmacokinetic study

Contact Info

Product

Resources

About